This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
infected cells | 160 |
viral rna | 134 |
nanotrap particles | 118 |
dengue virus | 111 |
ebola virus | 104 |
virus infection | 100 |
public health | 98 |
zika virus | 95 |
immune response | 84 |
chikungunya virus | 84 |
japanese encephalitis | 84 |
vector control | 80 |
confinement housing | 80 |
mg ml | 71 |
encephalitis virus | 68 |
fever virus | 68 |
room temperature | 66 |
hemorrhagic fever | 66 |
infectious diseases | 63 |
rift valley | 61 |
viral replication | 59 |
health organization | 59 |
valley fever | 59 |
cord uid | 58 |
negl trop | 58 |
trop dis | 58 |
doc id | 58 |
rabies virus | 58 |
dis doi | 58 |
plos negl | 58 |
neutralizing antibodies | 57 |
vero cells | 56 |
world health | 54 |
monoclonal antibodies | 53 |
post infection | 53 |
dengue fever | 53 |
rna synthesis | 52 |
sg assembly | 47 |
mouse model | 47 |
fecal samples | 46 |
severe dengue | 46 |
pfu ml | 45 |
human rabies | 45 |
significantly higher | 45 |
previously described | 44 |
days post | 43 |
virus replication | 43 |
host factors | 43 |
mo groups | 42 |
nipah virus | 41 |
respiratory syndrome | 41 |
infectious disease | 41 |
monoclonal antibody | 40 |
aedes aegypti | 40 |
mg kg | 40 |
acute respiratory | 40 |
years old | 39 |
mf prevalence | 39 |
fusion proteins | 38 |
serum samples | 38 |
sierra leone | 38 |
jev mo | 37 |
nsg mice | 37 |
immune responses | 36 |
dengue cases | 36 |
viral protein | 35 |
performed using | 35 |
cell lines | 35 |
jev sc | 35 |
amino acid | 35 |
disease control | 35 |
isothermal amplification | 35 |
amino acids | 35 |
chain reaction | 34 |
polymerase chain | 34 |
mass spectrometry | 34 |
zikv infection | 34 |
detection limit | 33 |
nucleic acid | 33 |
plaque assays | 33 |
fruit bats | 33 |
dry matter | 33 |
fecal dry | 33 |
hours post | 33 |
lassa fever | 32 |
wt mice | 32 |
weight loss | 32 |
vaccinia virus | 32 |
severe acute | 32 |
novel coronavirus | 32 |
united states | 31 |
described previously | 31 |
cell culture | 31 |
chikv infection | 31 |
west nile | 31 |
dengue control | 30 |
risk factors | 30 |
blood samples | 30 |
molecular mimicry | 29 |
western blotting | 29 |
mm tris | 29 |
oxidative stress | 29 |
neglected tropical | 29 |
dengue transmission | 29 |
neutralizing antibody | 29 |
canine rabies | 29 |
bovine serum | 29 |
immunized mice | 29 |
denv infection | 29 |
infection rates | 28 |
mediated isothermal | 28 |
negative control | 28 |
day post | 28 |
data streams | 28 |
equine encephalitis | 28 |
feline sporotrichosis | 28 |
infectious virus | 28 |
febrile illness | 28 |
plaque assay | 27 |
andv diii | 27 |
may also | 27 |
rabies control | 27 |
neutralizing activity | 27 |
reverse transcription | 27 |
nile virus | 27 |
animal models | 27 |
virus disease | 27 |
class ii | 27 |
dengue infection | 27 |
host cell | 27 |
infected mice | 27 |
onchocerca volvulus | 26 |
statistically significant | 26 |
general transcription | 26 |
stem region | 26 |
severe patients | 26 |
west africa | 26 |
pfu mice | 26 |
binding activity | 25 |
flow cytometry | 25 |
viral genome | 25 |
fusion protein | 25 |
mycobacterium ulcerans | 25 |
time points | 25 |
protective immunity | 25 |
endemic countries | 25 |
chadox niv | 25 |
western blot | 25 |
lymphatic filariasis | 25 |
spleen cells | 24 |
sporothrix schenckii | 24 |
viral infection | 24 |
marburg virus | 24 |
significantly lower | 24 |
rabies diagnosis | 24 |
rna binding | 24 |
normal controls | 24 |
buruli ulcer | 24 |
antibody response | 24 |
specific antibodies | 23 |
low ph | 23 |
cruzi oligoc | 23 |
tropical diseases | 23 |
animal care | 23 |
formalin inactivation | 23 |
well plates | 23 |
developing countries | 23 |
puerto rico | 23 |
ng ml | 23 |
nakayama virus | 23 |
vaccinated mice | 23 |
box stall | 23 |
fisher scientific | 22 |
transcription inhibition | 22 |
plasma cortisol | 22 |
severe anemia | 22 |
venezuelan equine | 22 |
surveillance data | 22 |
pd deficiency | 22 |
emerging infectious | 22 |
data assimilation | 22 |
membrane fusion | 22 |
kda gene | 22 |
previously reported | 22 |
saharan africa | 22 |
immune system | 21 |
multilocularis infection | 21 |
veroe cells | 21 |
semliki forest | 21 |
aedes albopictus | 21 |
cell line | 21 |
forest virus | 21 |
dub activity | 21 |
syndrome coronavirus | 21 |
body weight | 21 |
th dpi | 21 |
male mice | 21 |
jev infection | 21 |
mutant viruses | 21 |
control mice | 21 |
envelope protein | 21 |
chagas disease | 21 |
infected animals | 21 |
housing calves | 21 |
host transcription | 21 |
structural proteins | 21 |
endemic areas | 21 |
determined using | 21 |
ge healthcare | 21 |
vaccine candidate | 21 |
life cycle | 21 |
previous studies | 20 |
purified dna | 20 |
viral infections | 20 |
severe illness | 20 |
deficient individuals | 20 |
model predictions | 20 |
mice infected | 20 |
binding protein | 20 |
one hour | 20 |
samples collected | 20 |
cov rbd | 20 |
host immune | 20 |
nanotrap particle | 20 |
niv malaysia | 20 |
vaccinated animals | 20 |
mouse models | 20 |
chimeric viruses | 19 |
dengue hemorrhagic | 19 |
complete protection | 19 |
domestic dog | 19 |
stem cells | 19 |
rna polymerase | 19 |
pcr assay | 19 |
animal model | 19 |
echinococcus multilocularis | 19 |
trypanosoma cruzi | 19 |
significant difference | 19 |
virus glycoprotein | 19 |
diseases surveillance | 19 |
lethal challenge | 19 |
stem peptides | 19 |
closely related | 19 |
viral titers | 19 |
south africa | 19 |
dog rabies | 19 |
vad male | 19 |
cell responses | 19 |
time course | 19 |
rna viruses | 19 |
infected patients | 18 |
single dose | 18 |
denv rna | 18 |
clinical characteristics | 18 |
lf models | 18 |
institutional animal | 18 |
high levels | 18 |
selection bias | 18 |
southeast asia | 18 |
clinical features | 18 |
life technologies | 18 |
analyzed using | 18 |
calf model | 18 |
matter percentage | 18 |
polyclonal antibody | 18 |
antibody responses | 18 |
ii fusion | 18 |
box stalls | 18 |
fecal output | 18 |
type i | 18 |
thermo fisher | 18 |
present study | 18 |
cryptosporidium parvum | 18 |
innate immune | 18 |
cells infected | 18 |
total fecal | 18 |
confirmed cases | 18 |
whole blood | 18 |
pocket warmer | 18 |
otu domain | 18 |
buffered saline | 18 |
ifnar ko | 18 |
antibiotic treatment | 18 |
rapid detection | 17 |
molecular weight | 17 |
normal control | 17 |
nss protein | 17 |
data stream | 17 |
host proteins | 17 |
communicable diseases | 17 |
monocyte cultures | 17 |
antigenic structure | 17 |
wt nss | 17 |
taken together | 17 |
gene expression | 17 |
dengue severity | 17 |
infected monocytes | 17 |
virus rna | 17 |
climate change | 17 |
fetal bovine | 17 |
real time | 17 |
even though | 17 |
congo hemorrhagic | 16 |
experimental infection | 16 |
domain iii | 16 |
viral antigens | 16 |
middle east | 16 |
oocyst shedding | 16 |
statistical analysis | 16 |
results indicate | 16 |
copies per | 16 |
lethal dose | 16 |
virus type | 16 |
female mice | 16 |
modified vaccinia | 16 |
data collected | 16 |
disease surveillance | 16 |
infected individuals | 16 |
cellular stress | 16 |
death reporting | 16 |
wild type | 16 |
time pcr | 16 |
jamaican fruit | 16 |
infected dogs | 16 |
samples obtained | 16 |
influenza virus | 16 |
fruit bat | 16 |
dengue prevention | 16 |
per reaction | 16 |
lysis buffer | 16 |
without nt | 16 |
significantly reduced | 16 |
bat exposures | 16 |
cell death | 16 |
laboratory animals | 16 |
control animals | 16 |
clinical specimens | 16 |
ko mice | 16 |
niv bangladesh | 16 |
brain tissue | 16 |
rna extraction | 16 |
three models | 16 |
borne diseases | 16 |
prv infection | 16 |
nss mutants | 16 |
viral proteins | 16 |
target cells | 16 |
serial dilutions | 16 |
dna polymerase | 15 |
treatment failure | 15 |
per group | 15 |
blt mice | 15 |
recombinase polymerase | 15 |
envelope glycoprotein | 15 |
antibody titers | 15 |
ms identified | 15 |
severe fever | 15 |
alt values | 15 |
recombinant protein | 15 |
study end | 15 |
immunodeficiency virus | 15 |
goat anti | 15 |
immune evasion | 15 |
lateral flow | 15 |
binding domain | 15 |
control efforts | 15 |
guano miners | 15 |
principal findings | 15 |
prevalence data | 15 |
less likely | 15 |
rolling circle | 15 |
viral particles | 15 |
cell viability | 15 |
whole virus | 15 |
diagnostic tests | 15 |
chikv infected | 15 |
clinical trials | 15 |
higher proportion | 15 |
thrombocytopenia syndrome | 15 |
commercially available | 15 |
tissue culture | 15 |
important role | 15 |
informed consent | 15 |
lujo virus | 14 |
phosphate dehydrogenase | 14 |
cell entry | 14 |
linked immunosorbent | 14 |
molecular biology | 14 |
tropical medicine | 14 |
time point | 14 |
polymerase amplification | 14 |
results obtained | 14 |
high sensitivity | 14 |
independent experiments | 14 |
humanized mice | 14 |
low levels | 14 |
yellow fever | 14 |
binding proteins | 14 |
evaluated using | 14 |
virus challenge | 14 |
mab binding | 14 |
cellular proteins | 14 |
dna vaccine | 14 |
dna extracts | 14 |
passive transfer | 14 |
patients infected | 14 |
human infection | 14 |
human primates | 14 |
use committee | 14 |
control programs | 14 |
copy number | 14 |
haemorrhagic fever | 14 |
weeks post | 14 |
control programmes | 14 |
capsid protein | 14 |
many countries | 14 |
circle amplification | 14 |
host cells | 14 |
viral load | 14 |
dog populations | 14 |
human cases | 14 |
dog vaccination | 14 |
stall calves | 14 |
onnv nsp | 14 |
monkeypox virus | 14 |
significantly different | 14 |
current study | 13 |
serially diluted | 13 |
cell cultures | 13 |
pcr assays | 13 |
global health | 13 |
health care | 13 |
south america | 13 |
human cells | 13 |
latin america | 13 |
rabbit anti | 13 |
protective efficacy | 13 |
viral membrane | 13 |
test results | 13 |
domestic dogs | 13 |
animals challenged | 13 |
acute febrile | 13 |
detected using | 13 |
new world | 13 |
longitudinal data | 13 |
supportive care | 13 |
rna virus | 13 |
coronavirus disease | 13 |
similar results | 13 |
great ape | 13 |
three different | 13 |
early diagnosis | 13 |
relative cfr | 13 |
mice immunized | 13 |
immunosorbent assay | 13 |
diagnostic test | 13 |
disease outbreaks | 13 |
nitric oxide | 13 |
like particles | 13 |
significantly increased | 13 |
mm nacl | 13 |
ebola epidemic | 13 |
key west | 13 |
liver failure | 13 |
chikv envelope | 13 |
helminth infection | 13 |
blot analysis | 13 |
treated cells | 13 |
human immune | 13 |
specific antibody | 13 |
clinical samples | 13 |
structural protein | 13 |
antibody detection | 13 |
control group | 13 |
dengue outbreaks | 13 |
dependent rna | 13 |
protein expression | 13 |
washed twice | 13 |
murine model | 13 |
surveillance system | 13 |
mortality rates | 12 |
viral inactivation | 12 |
syrian hamsters | 12 |
viral loads | 12 |
virus envelope | 12 |
income countries | 12 |
indirect immunofluorescence | 12 |
cell surface | 12 |
rabies deaths | 12 |
st century | 12 |
control diet | 12 |
fusion loop | 12 |
clinical course | 12 |
conventional lamp | 12 |
reaction mixture | 12 |
imported cases | 12 |
severe disease | 12 |
warning signs | 12 |
vaccine candidates | 12 |
infection rate | 12 |
per gram | 12 |
small animal | 12 |
lamp assays | 12 |
endemic regions | 12 |
great apes | 12 |
clinical presentation | 12 |
genbank accession | 12 |
washed times | 12 |
accession number | 12 |
bone marrow | 12 |
also used | 12 |
mda data | 12 |
enveloped viruses | 12 |
genomic dna | 12 |
sterile pbs | 12 |
community engagement | 12 |
nonhuman primates | 12 |
patients consulting | 12 |
nss gene | 12 |
type ii | 12 |
control programme | 12 |
viral dna | 12 |
systemic bacterial | 12 |
wide range | 12 |
dengue patients | 12 |
positive results | 12 |
fluid therapy | 12 |
viral fusion | 12 |
completely protected | 12 |
clinical manifestations | 12 |
uprt cells | 12 |
mda mf | 12 |
clinical diagnosis | 12 |
results suggest | 12 |
nonstructural protein | 12 |
significant differences | 12 |
echinococcus granulosus | 12 |
cd cd | 12 |
rousettus aegyptiacus | 12 |
east respiratory | 12 |
transmission dynamics | 12 |
mouse monoclonal | 12 |
andv gc | 12 |
forming units | 12 |
pilot study | 12 |
molecular epidemiology | 12 |
infected group | 12 |
deaths reported | 12 |
immune cells | 12 |
course study | 12 |
small numbers | 12 |
lf elimination | 12 |
mononuclear cells | 12 |
viral supernatants | 12 |
inhibition function | 12 |
fusion process | 12 |
virus vaccine | 12 |
results demonstrate | 12 |
african green | 12 |
gel electrophoresis | 12 |
thank dr | 12 |
protein ns | 12 |
future studies | 12 |
global burden | 12 |
chikv vlps | 12 |
results show | 11 |
cell proliferation | 11 |
protein kinase | 11 |
dna extracted | 11 |
target dna | 11 |
respiratory tract | 11 |
cells showed | 11 |
also observed | 11 |
confidence interval | 11 |
environmental management | 11 |
type diabetes | 11 |
highly conserved | 11 |
vector specificity | 11 |
mo treatment | 11 |
rna replication | 11 |
orientia tsutsugamushi | 11 |
satellite dna | 11 |
ms ms | 11 |
antibodies elicited | 11 |
positive dengue | 11 |
way anova | 11 |
kg day | 11 |
extraction kit | 11 |
dengue illness | 11 |
clinical management | 11 |
sindbis virus | 11 |
broad spectrum | 11 |
best data | 11 |
page followed | 11 |
joint pain | 11 |
plasmid dna | 11 |
previous study | 11 |
naturally infected | 11 |
social mobilization | 11 |
hendra virus | 11 |
per well | 11 |
clinical laboratory | 11 |
mo treatments | 11 |
ic samples | 11 |
graphpad prism | 11 |
data suggest | 11 |
worms recovered | 11 |
new york | 11 |
bovine herpesvirus | 11 |
early detection | 11 |
per mouse | 11 |
secondary structure | 11 |
typhi dna | 11 |
rabid animal | 11 |
north queensland | 11 |
sense rna | 11 |
cell fusion | 11 |
andv glycoproteins | 11 |
dendritic cells | 11 |
afi cases | 11 |
first time | 11 |
jiangsu province | 11 |
recent study | 11 |
dependent manner | 11 |
systematic review | 11 |
bat bite | 11 |
experimentally infected | 11 |
incubated overnight | 11 |
virus outbreak | 11 |
pcr positive | 11 |
mosquito breeding | 11 |
determine whether | 11 |
amplification assay | 11 |
lamp assay | 11 |
retrospective study | 11 |
several studies | 11 |
dna vaccines | 11 |
rabies vaccination | 11 |
plasma membrane | 11 |
total rna | 11 |
animal welfare | 11 |
control measures | 11 |
fold increase | 11 |
ocp antibody | 11 |
lethal sftsv | 11 |
chikungunya fever | 11 |
tropical disease | 11 |
two weeks | 11 |
log oocysts | 11 |
sore throat | 11 |
early warning | 11 |
mice per | 11 |
stem fragments | 11 |
pcr products | 11 |
stress response | 11 |
animals treated | 11 |
virus genome | 11 |
cell extracts | 11 |
morpholino oligomers | 11 |
biological samples | 11 |
mice vaccinated | 11 |
plasma samples | 10 |
reverse primer | 10 |
jev antigen | 10 |
animal experiments | 10 |
viral amplification | 10 |
written informed | 10 |
protects mice | 10 |
new guinea | 10 |
cells well | 10 |
ebola outbreak | 10 |
vaccination campaigns | 10 |
risk assessment | 10 |
control dengue | 10 |
samples without | 10 |
serum albumin | 10 |
control groups | 10 |
bd biosciences | 10 |
pregnant women | 10 |
decision making | 10 |
reverse transcriptase | 10 |
virus transmission | 10 |
type chikv | 10 |
achieve mf | 10 |
th day | 10 |
prediction uncertainty | 10 |
cell lysate | 10 |
denv serotypes | 10 |
fecal oocyst | 10 |
acute liver | 10 |
central africa | 10 |
per year | 10 |
disease severity | 10 |
culture media | 10 |
protein synthesis | 10 |
age groups | 10 |
source reduction | 10 |
cell types | 10 |
factor viia | 10 |
crystal structure | 10 |
san diego | 10 |
treatment groups | 10 |
cd stem | 10 |
viral antigen | 10 |
health services | 10 |
control activities | 10 |
virus isolation | 10 |
ulcerans infection | 10 |
reported deaths | 10 |
chikv env | 10 |
alveolar echinococcosis | 10 |
cell lysates | 10 |
reporter gene | 10 |
restriction enzyme | 10 |
methodology principal | 10 |
virus strain | 10 |
aedes mosquitoes | 10 |
human monoclonal | 10 |
respiratory syncytial | 10 |
extracted dna | 10 |
live attenuated | 10 |
mortality rate | 10 |
singapore communicable | 10 |
data analysis | 10 |
large numbers | 10 |
treg cells | 10 |
rabies cases | 10 |
ihc analysis | 10 |
host response | 10 |
commonly used | 10 |
cryptococcus neoformans | 10 |
final concentration | 10 |
positive control | 10 |
deficient monocyte | 10 |
containing fbs | 10 |
dna extraction | 10 |
prospective study | 10 |
ut epo | 10 |
sftsv infection | 10 |
survey data | 10 |
treated animals | 10 |
predictive performance | 9 |
hospitalized patients | 9 |
proinflammatory cytokines | 9 |
footpad swelling | 9 |
culture medium | 9 |
three times | 9 |
red blood | 9 |
immune enhancement | 9 |
drug discovery | 9 |
dengue vaccine | 9 |
bat lyssaviruses | 9 |
causative agent | 9 |
cchfv rdrp | 9 |
may lead | 9 |
severe cases | 9 |
denv amplification | 9 |
bacterial levels | 9 |
detection limits | 9 |
cerebrospinal fluid | 9 |
dairy calves | 9 |
severe covid | 9 |
vesicular stomatitis | 9 |
provide protection | 9 |
phosphate buffered | 9 |
mo treated | 9 |
time series | 9 |
local transmission | 9 |
dhf dss | 9 |
cell response | 9 |
american journal | 9 |
full length | 9 |
two groups | 9 |
secondary antibody | 9 |
santa cruz | 9 |
recent studies | 9 |
leprosy reactions | 9 |
previously shown | 9 |
conclusions significance | 9 |
cmv promoter | 9 |
cellular immunity | 9 |
two different | 9 |
based vaccine | 9 |
whole cell | 9 |
mouse anti | 9 |
pcr product | 9 |
xcp cassette | 9 |
denv host | 9 |
three independent | 9 |
eye pain | 9 |
findings suggest | 9 |
pteropine orthoreovirus | 9 |
od values | 9 |
epidemiological studies | 9 |
milk replacer | 9 |
contact tracing | 9 |
therapeutic agents | 9 |
mutant virus | 9 |
expression levels | 9 |
large number | 9 |
wild great | 9 |
recombinant factor | 9 |
papua new | 9 |
water bath | 9 |
vast majority | 9 |
mouse strains | 9 |
national institute | 9 |
better understand | 9 |
protective effect | 9 |
lower levels | 9 |
virus entry | 9 |
host factor | 9 |
breeding sites | 9 |
skim milk | 9 |
collaborative cross | 9 |
results showed | 9 |
passive immunization | 9 |
subunit vaccine | 9 |
reported cases | 9 |
medical research | 9 |
southern africa | 9 |
jev genome | 9 |
social media | 9 |
information gained | 9 |
dengue viruses | 9 |
acute phase | 9 |
stomatitis virus | 9 |
serial dilution | 9 |
humoral immune | 9 |
os cells | 9 |
vaccinia ankara | 9 |
informed models | 9 |
median age | 9 |
post inoculation | 9 |
early clinical | 9 |
virus titer | 9 |
mammalian cells | 9 |
plos neglected | 9 |
samples showed | 9 |
alt iu | 9 |
fungal infections | 9 |
viral hemorrhagic | 9 |
pbs containing | 9 |
dengue epidemic | 9 |
mrna transcription | 9 |
mass drug | 9 |
oocysts per | 9 |
specific primers | 9 |
agarose gel | 9 |
acute dengue | 9 |
new england | 9 |
syncytial virus | 9 |
mda coverage | 9 |
inactivated jev | 9 |
induce cellular | 9 |
genomic copies | 9 |
stress granules | 9 |
mortality surveillance | 9 |
considered positive | 9 |
identified factors | 9 |
laboratory confirmation | 9 |
aminotransferase levels | 9 |
well plate | 9 |
post transfection | 9 |
may contribute | 9 |
gc fragments | 9 |
data set | 9 |
rvfv virulence | 8 |
culture supernatants | 8 |
stem cell | 8 |
gc glycoproteins | 8 |
budget cuts | 8 |
blocking buffer | 8 |
peak values | 8 |
fusion activity | 8 |
nucleic acids | 8 |
parameter space | 8 |
sequence alignment | 8 |
virus antigen | 8 |
stranded rna | 8 |
case fatality | 8 |
diffusion chambers | 8 |
endothelial cells | 8 |
established infection | 8 |
positive cases | 8 |
clinical illness | 8 |
high mortality | 8 |
two peptides | 8 |
mycobacterium tuberculosis | 8 |
proteasome pathway | 8 |
pcr reaction | 8 |
fold increases | 8 |
viral particle | 8 |
rna genome | 8 |
control study | 8 |
virus polymerase | 8 |
human sporotrichosis | 8 |
recent years | 8 |
may affect | 8 |
red arrows | 8 |
inactivated nakayama | 8 |
copies ml | 8 |
antimalarial drugs | 8 |
nested pcr | 8 |
incubation period | 8 |
fusion peptide | 8 |
scrub typhus | 8 |
laboratory animal | 8 |
population growth | 8 |
human proteins | 8 |
live virus | 8 |
effective treatment | 8 |
dna amplification | 8 |
peripheral blood | 8 |
causal interpretation | 8 |
particle incubation | 8 |
global vector | 8 |
black grain | 8 |
normal limits | 8 |
stress granule | 8 |
diii proteins | 8 |
plaque forming | 8 |
mosquito control | 8 |
early stages | 8 |
protective immune | 8 |
mechanical ventilation | 8 |
survivorship bias | 8 |
rabbit polyclonal | 8 |
untranslated region | 8 |
mouse serum | 8 |
partial protection | 8 |
scid mice | 8 |
wash buffer | 8 |
plasmid encoding | 8 |
within normal | 8 |
andv infection | 8 |
epo cells | 8 |
viral entry | 8 |
extracted using | 8 |
immune serum | 8 |
borne prv | 8 |
analysis using | 8 |
rapid identification | 8 |
type mice | 8 |
copy numbers | 8 |
filovirus infection | 8 |
participants years | 8 |
jev serocomplex | 8 |
health problem | 8 |
cfc samples | 8 |
thermo scientific | 8 |
kindly provided | 8 |
isolated otu | 8 |
dna sequences | 8 |
virus vp | 8 |
data obtained | 8 |
also found | 8 |
human antibody | 8 |
amplification method | 8 |
ethics committee | 8 |
relative information | 8 |
direct contact | 8 |
serum specimens | 8 |
disease caused | 8 |
rdrp activity | 8 |
data collection | 8 |
puuv hdiii | 8 |
vad mice | 8 |
infection may | 8 |
exogenous diii | 8 |
construction sites | 8 |
previously published | 8 |
strongyloides stercoralis | 8 |
onn chik | 8 |
bias may | 8 |
mouse igg | 8 |
disease burden | 8 |
vero cell | 8 |
may provide | 8 |
providing protection | 8 |
syndrome virus | 8 |
protein interactions | 8 |
tissue damage | 8 |
postexposure prophylaxis | 8 |
units ml | 8 |
viral challenge | 8 |
conserved among | 8 |
interferon signaling | 8 |
magnetic beads | 8 |
human igg | 8 |
cloned viruses | 8 |
relatively high | 8 |
drug administration | 8 |
three days | 8 |
obtained using | 8 |
zikv replication | 8 |
alexa fluor | 8 |
strand rna | 8 |
weighted variance | 8 |
including dengue | 8 |
showed similar | 8 |
translation initiation | 8 |
vaccine development | 8 |
stress responses | 8 |
time rt | 8 |
jev vaccine | 8 |
molecular mass | 8 |
structural regions | 8 |
inhibitory activity | 8 |
institutional review | 8 |
exposure prophylaxis | 8 |
dengue case | 8 |
negative controls | 8 |
early stage | 8 |
highly pathogenic | 8 |
respiratory disease | 8 |
like protein | 8 |
peptides derived | 8 |
based vector | 8 |
mouse brain | 8 |
kda protein | 8 |
redox state | 8 |
secondary antibodies | 8 |
length cchfv | 8 |
inhibitor cocktail | 8 |
total amount | 8 |
also present | 8 |
review board | 8 |
essential medium | 8 |
denv titers | 8 |
penicillin streptomycin | 8 |
viral envelope | 8 |
logistic regression | 8 |
aegypti mosquitoes | 8 |
fort collins | 8 |
population density | 7 |
recombinant mva | 7 |
dna synthesis | 7 |
sporothrix brasiliensis | 7 |
gold standard | 7 |
monitoring system | 7 |
five patients | 7 |
rabies elimination | 7 |
humoral response | 7 |
cytopathic effect | 7 |
natural reservoir | 7 |
previous reports | 7 |
gm transfer | 7 |
also shown | 7 |
adult dengue | 7 |
infected persons | 7 |
lower panels | 7 |
cruzi detection | 7 |
rabies prevention | 7 |
complement component | 7 |
advisory committee | 7 |
predicted diii | 7 |
formalin treatment | 7 |
small number | 7 |
bat rabies | 7 |
segmented negative | 7 |
biosafety level | 7 |
week old | 7 |
following jev | 7 |
studies conducted | 7 |
nucleotide analogues | 7 |
first week | 7 |
data scenarios | 7 |
may result | 7 |
purified using | 7 |
health system | 7 |
chikv disease | 7 |
relatively small | 7 |
survival rate | 7 |
rvfv nss | 7 |
per ml | 7 |
based assay | 7 |
urine samples | 7 |
singapore dengue | 7 |
dengue outbreak | 7 |
neurological signs | 7 |
horseradish peroxidase | 7 |
using dna | 7 |
may need | 7 |
reduction neutralization | 7 |
grain eumycetoma | 7 |
gambiae mosquitoes | 7 |
urban areas | 7 |
chik immune | 7 |
routine mortality | 7 |
conjugated secondary | 7 |
labeled rna | 7 |
jev vaccines | 7 |
mice exhibited | 7 |
dmem supplemented | 7 |
limited number | 7 |
phylogenetic analysis | 7 |
virus capture | 7 |
rickettsial diseases | 7 |
time period | 7 |
reporting system | 7 |
discovery rate | 7 |
diagnostic accuracy | 7 |
infected groups | 7 |
data represent | 7 |
sftsv challenge | 7 |
available beads | 7 |
human monkeypox | 7 |
vol vol | 7 |
becton dickinson | 7 |
lassa virus | 7 |
effective vaccine | 7 |
virus titers | 7 |
transcription suppression | 7 |
intranasally inoculated | 7 |
ebola hemorrhagic | 7 |
cell membrane | 7 |
padlock probes | 7 |
sars cov | 7 |
diagnostic testing | 7 |
human immunodeficiency | 7 |
antirabies prophylaxis | 7 |
effector cells | 7 |
healthcare workers | 7 |
human host | 7 |
forward primer | 7 |
also evaluated | 7 |
activated microglia | 7 |
older adults | 7 |
mm edta | 7 |
inhibit ifn | 7 |
sample size | 7 |
dna vaccination | 7 |
increased risk | 7 |
age group | 7 |
laboratory staff | 7 |
ros levels | 7 |
standard deviation | 7 |
virulence factor | 7 |
ntd programs | 7 |
post challenge | 7 |
ebov infection | 7 |
animal studies | 7 |
liquid chromatography | 7 |
two doses | 7 |
like symptoms | 7 |
formic acid | 7 |
antibody binding | 7 |
transferred onto | 7 |
present lf | 7 |
inflammatory response | 7 |
internal control | 7 |
orv illness | 7 |
five cases | 7 |
chik onn | 7 |
described elsewhere | 7 |
genetic diversity | 7 |
mice died | 7 |
without affecting | 7 |
plasma leakage | 7 |
salivary gland | 7 |
cells using | 7 |
genome transcription | 7 |
assays using | 7 |
million cases | 7 |
sri lanka | 7 |
bat species | 7 |
following infection | 7 |
dengue vector | 7 |
bona fide | 7 |
positive cells | 7 |
sample preparation | 7 |
target sequence | 7 |
newspaper coverage | 7 |
sybr green | 7 |
right panels | 7 |
crystal violet | 7 |
scid il | 7 |
potential role | 7 |
west african | 7 |
outside wuhan | 7 |
clinical data | 7 |
nuclear factor | 7 |
cortisol levels | 7 |
least one | 7 |
sg markers | 7 |
plasmodium falciparum | 7 |
il rg | 7 |
copies reaction | 7 |
hela cells | 7 |
protein vp | 7 |
deficient subjects | 7 |
economic burden | 7 |
human mabs | 7 |
i pneumocytes | 7 |
zaire ebolavirus | 7 |
successfully used | 7 |
primary antibody | 7 |
taqman real | 7 |
investigated whether | 7 |
without warning | 7 |
np antibodies | 7 |
plasmids encoding | 7 |
liver aminotransferase | 7 |
mm mgcl | 7 |
carboxymuconate cyclase | 7 |
oropharyngeal swabs | 7 |
fine needle | 7 |
lower detection | 7 |
cells treated | 7 |
human disease | 7 |
blue arrows | 7 |
electron microscopy | 7 |
grain mycetoma | 7 |
serocomplex cross | 7 |
will also | 7 |
laboratory findings | 7 |
false discovery | 7 |
parameter correlations | 7 |
mock infected | 7 |
opposite template | 7 |
class i | 7 |
umbilical cord | 7 |
following challenge | 7 |
acute undifferentiated | 7 |
control monocyte | 7 |
significantly decreased | 7 |
among patients | 7 |
based vectors | 7 |
alt levels | 7 |
matrix protein | 7 |
primer template | 7 |
active site | 7 |
using anti | 7 |
highly specific | 7 |
old world | 7 |
lethal infection | 7 |
peptide pools | 7 |
east asia | 7 |
inflammatory cytokines | 7 |
lineage i | 7 |
animal hosts | 7 |
detection probes | 7 |
reservoir animals | 7 |
blood cells | 7 |
host transcriptional | 7 |
fold serial | 7 |
survival curve | 7 |
model uncertainty | 7 |
typhoidal salmonella | 7 |
cell activation | 7 |
also reported | 7 |
virus ankara | 7 |
cell monolayers | 7 |
parenteral vaccination | 7 |
bodily fluids | 7 |
rna silencing | 7 |
acid sequences | 7 |
analysis tools | 7 |
well viral | 7 |
dengue incidence | 7 |
nucleocapsid proteins | 7 |
mutated nss | 7 |
prism software | 7 |
clinical signs | 7 |
necrosis factor | 7 |
uv light | 7 |
confirmed covid | 7 |
ebola response | 7 |
symptom onset | 7 |
individuals may | 7 |
reunion island | 6 |
like illness | 6 |
ast iu | 6 |
protein region | 6 |
single mutation | 6 |
control monocytes | 6 |
ii restriction | 6 |
nss mutant | 6 |
high prevalence | 6 |
will allow | 6 |
two independent | 6 |
vector surveillance | 6 |
mice received | 6 |
spotted fever | 6 |
laboratory tests | 6 |
transcription factor | 6 |
field studies | 6 |
virus neutralization | 6 |
rna primer | 6 |
key terms | 6 |
mer product | 6 |
lyssavirus genus | 6 |
validation studies | 6 |
pcr amplification | 6 |
terminal region | 6 |
percent survival | 6 |
adult worms | 6 |
septic shock | 6 |
blood sample | 6 |
total number | 6 |
renilla luciferase | 6 |
year old | 6 |
ml reaction | 6 |
infected controls | 6 |
neutralizing human | 6 |
undifferentiated febrile | 6 |
dengue infections | 6 |
cystic echinococcosis | 6 |
three lf | 6 |
specific cd | 6 |
surveillance systems | 6 |
oral ribavirin | 6 |
patients may | 6 |
might also | 6 |
physical exam | 6 |
cell supernatants | 6 |
virus neutralizing | 6 |
tris ph | 6 |
chimeric virus | 6 |
welfare act | 6 |
severe forms | 6 |
log decrease | 6 |
adult participants | 6 |
mrna synthesis | 6 |
earlier time | 6 |
borne disease | 6 |
guano mining | 6 |
virus nss | 6 |
development efforts | 6 |
specifically designed | 6 |
immune cd | 6 |
uninfected cells | 6 |
false positive | 6 |
vaccine provides | 6 |
specific peptide | 6 |
cells expressing | 6 |
luciferase reporter | 6 |
conjugated goat | 6 |
humoral immunity | 6 |
children years | 6 |
dengue risk | 6 |
protease inhibitor | 6 |
panels indicate | 6 |
bat populations | 6 |
lung tissue | 6 |
elevated ast | 6 |
hela uprt | 6 |
target gene | 6 |
critical role | 6 |
specific data | 6 |
microglial cells | 6 |
information system | 6 |
cross contamination | 6 |
national parks | 6 |
stranded dna | 6 |
capture rvfv | 6 |
mortem diagnosis | 6 |
viral titer | 6 |
chikv infections | 6 |
molecular mechanisms | 6 |
kind gift | 6 |
abdominal pain | 6 |
field samples | 6 |
jev vlps | 6 |
national health | 6 |
intensive care | 6 |
significant reduction | 6 |
product formation | 6 |
persistent arthralgia | 6 |
highly susceptible | 6 |
viral glycoproteins | 6 |
herd immunity | 6 |
parameter estimates | 6 |
associated protein | 6 |
independently associated | 6 |
sense molecules | 6 |
reactive mabs | 6 |
following vaccination | 6 |
case reporting | 6 |
infective viral | 6 |
health authorities | 6 |
poor settings | 6 |
receptor binding | 6 |
parental chikv | 6 |
median ast | 6 |
mice resulted | 6 |
test whether | 6 |
case study | 6 |
replication kinetics | 6 |
democratic republic | 6 |
polyacrylamide gel | 6 |
control cells | 6 |
roc curve | 6 |
statistical analyses | 6 |
blood donors | 6 |
recent reports | 6 |
treatment options | 6 |
safe burial | 6 |
strict accordance | 6 |
traditional disease | 6 |
cells per | 6 |
phase ii | 6 |
marburg viruses | 6 |
virus antibodies | 6 |
dna sequencing | 6 |
high titers | 6 |
th immune | 6 |
live nakayama | 6 |
zoonotic diseases | 6 |
per cell | 6 |
circular dichroism | 6 |
seafood market | 6 |
confirmed patients | 6 |
three decades | 6 |
data show | 6 |
supporting information | 6 |
fusion conformation | 6 |
control samples | 6 |
gene sequence | 6 |
polypyrimidine tract | 6 |
infected wt | 6 |
molecular clock | 6 |
volvulus infection | 6 |
shed virus | 6 |
adaptive immunity | 6 |
highly efficient | 6 |
good laboratory | 6 |
terrestrial mammals | 6 |
resistant salmonella | 6 |
measured using | 6 |
gc protein | 6 |
brain sections | 6 |
mf survey | 6 |
tyrosine kinase | 6 |
denv infected | 6 |
calf serum | 6 |
molecular detection | 6 |
transdermal bat | 6 |
million people | 6 |
highly sensitive | 6 |
metal ions | 6 |
investigate whether | 6 |
pathological changes | 6 |
supernatants containing | 6 |
rabid dog | 6 |
typhimurium infection | 6 |
immunohistochemical test | 6 |
control response | 6 |
encephalitis www | 6 |
log fl | 6 |
human antibodies | 6 |
higher viral | 6 |
clinical findings | 6 |
laboratory features | 6 |
hydrogen peroxide | 6 |
bite injuries | 6 |
th response | 6 |
simian immunodeficiency | 6 |
sporothrix spp | 6 |
epidemiological data | 6 |
cell fitness | 6 |
primers used | 6 |
green monkeys | 6 |
software program | 6 |
nonstructural proteins | 6 |
transfection efficiency | 6 |
particle formation | 6 |
mosquito bites | 6 |
zikv antigen | 6 |
salmonella enterica | 6 |
expression cassette | 6 |
capture elisa | 6 |
artibeus jamaicensis | 6 |
performed according | 6 |
collected via | 6 |
mini kit | 6 |
nyong virus | 6 |
febrile illnesses | 6 |
nakayama strain | 6 |
taken daily | 6 |
chikv peptide | 6 |
time reverse | 6 |
ph incubation | 6 |
zikv rna | 6 |
cruz biotechnology | 6 |
health commission | 6 |
models may | 6 |
nonhuman primate | 6 |
host range | 6 |
ebolavirus antibodies | 6 |
mosquito infection | 6 |
high level | 6 |
data points | 6 |
receiver operating | 6 |
virus infections | 6 |
last years | 6 |
two days | 6 |
specimens collected | 6 |
neurological disorders | 6 |
operating characteristic | 6 |
ediii epitope | 6 |
hong kong | 6 |
platelet count | 6 |
may occur | 6 |
odds ratio | 6 |
rabies surveillance | 6 |
coronavirus infection | 6 |
showed mean | 6 |
infected individual | 6 |
parasite growth | 6 |
virus serotype | 6 |
tetravalent dengue | 6 |
least cells | 6 |
liquid nitrogen | 6 |
endemic control | 6 |
unexplained pneumonia | 6 |
management decision | 6 |
developing world | 6 |
negative samples | 6 |
viral hepatitis | 6 |
acute infection | 6 |
murine typhus | 6 |
equal volume | 6 |
hemorrhagic fevers | 6 |
dna kit | 6 |
four animals | 6 |
multiple sequence | 6 |
workers residents | 6 |
host components | 6 |
active surveillance | 6 |
rvfv mp | 6 |
viral capture | 6 |
technical assistance | 6 |
tandem mass | 6 |
disease virus | 6 |
regression analysis | 6 |
central america | 6 |
participants reported | 6 |
cytopathic effects | 6 |
sensitivity analysis | 6 |
one ml | 6 |
rapid diagnostic | 6 |
antigen preparations | 6 |
clinical development | 6 |
mice deficient | 6 |
hcl ph | 6 |
detection rate | 6 |
fold change | 6 |
viral diseases | 6 |
terminal residues | 6 |
ft cells | 6 |
genome sequencing | 6 |
cchfv otu | 6 |
rapid immunohistochemical | 6 |
siv vectors | 6 |
chikungunya viruses | 6 |
sample buffer | 6 |
dehydrogenase deficiency | 6 |
dengue clusters | 6 |
total volume | 6 |
light chains | 6 |
andv hdiii | 6 |
wildlife disease | 6 |
hantavirus gc | 6 |
total protein | 6 |
epithelial cells | 6 |
potentially rabid | 6 |
serum sample | 6 |
late stage | 6 |
blood cell | 6 |
mean peak | 6 |
attenuated vaccine | 6 |
early signals | 6 |
immune sera | 6 |
death occurred | 6 |
annual mda | 6 |
schenckii complex | 6 |
known denv | 6 |
borne encephalitis | 6 |
lowest entropy | 6 |
notifiable diseases | 6 |
plasma specimens | 6 |
stage larvae | 6 |
green monkey | 6 |
eg copro | 6 |
mosquito vector | 6 |
stall housing | 6 |
brain samples | 6 |
parasite load | 6 |
table shows | 6 |
cell signaling | 6 |
entropy values | 6 |
mosquito vectors | 6 |
cases reported | 6 |
mouse plasma | 6 |
somatic hypermutation | 6 |
immune cell | 6 |
virus associated | 6 |
structural basis | 6 |
vp may | 6 |
paracoccidioides brasiliensis | 6 |
human plasma | 6 |
gn gc | 6 |
polyacrylamide gels | 6 |
mutated vlp | 6 |
health decision | 6 |
parental onnv | 6 |
data demonstrated | 6 |
based assays | 6 |
cytokine production | 6 |
high throughput | 6 |
phage display | 6 |
stool sample | 6 |
recombinant viruses | 6 |
rangeli isolates | 6 |
least sg | 6 |
pdb entry | 6 |
vector laboratories | 6 |
gp expression | 6 |
transfected cells | 6 |
induced sg | 6 |
significant role | 6 |
temple workers | 6 |
antiviral response | 6 |
radiolabeled nucleotide | 6 |
data fusion | 6 |
life sciences | 6 |
equal volumes | 6 |
authors thank | 5 |
ml penicillin | 5 |
sucrose cushion | 5 |
also associated | 5 |
serum obtained | 5 |
southeast asian | 5 |
convenience sample | 5 |
platelet counts | 5 |
immunized mouse | 5 |
one day | 5 |
anopheles gambiae | 5 |
calibration curve | 5 |
eastern equine | 5 |
antibodies directed | 5 |
significant increase | 5 |
based detection | 5 |
chikv peptides | 5 |
leukemia virus | 5 |
ab responses | 5 |
epidemiological surveillance | 5 |
five years | 5 |
molecular determinants | 5 |
secondary transmission | 5 |
quantitative real | 5 |
light chain | 5 |
water content | 5 |
fatal outcome | 5 |
old female | 5 |
human transmission | 5 |
antiviral activity | 5 |
acid sequence | 5 |
mean titer | 5 |
terminal part | 5 |
expression cassettes | 5 |
virus serotypes | 5 |
mass vaccination | 5 |
family bunyaviridae | 5 |
guinea pigs | 5 |
hiv infection | 5 |
evaluate whether | 5 |
global distribution | 5 |
early identification | 5 |
previously established | 5 |
simian adenovirus | 5 |
bat caves | 5 |
rural tanzania | 5 |
respiratory infections | 5 |
sequence within | 5 |
metabolic syndrome | 5 |
infected mouse | 5 |
dhaka city | 5 |
town councils | 5 |
first step | 5 |
north american | 5 |
black bars | 5 |
remains unclear | 5 |
internal organs | 5 |
impaired ability | 5 |
specific monoclonal | 5 |
causative agents | 5 |
drug interventions | 5 |
spent media | 5 |
ebolavirus proteins | 5 |
test showed | 5 |
therapeutic antibodies | 5 |
human deaths | 5 |
human challenge | 5 |
envelope proteins | 5 |
rna processing | 5 |
immunoblot analysis | 5 |
parasite detection | 5 |
rabies postexposure | 5 |
using monoclonal | 5 |
deceased persons | 5 |
host protein | 5 |
fluorescent antibody | 5 |
dependent protein | 5 |
call center | 5 |
will require | 5 |
mgh strips | 5 |
gene encoding | 5 |
ebola cases | 5 |
emerging virus | 5 |
southern taiwan | 5 |
inhibit viral | 5 |
perinuclear region | 5 |
oocyst enumeration | 5 |
structural region | 5 |
different strains | 5 |
bacterial burden | 5 |
least two | 5 |
rheumatoid arthritis | 5 |
cell wall | 5 |
cellular rna | 5 |
dg hb | 5 |
vertical transmission | 5 |
infection surveillance | 5 |
individual model | 5 |
wolbachia mosquitoes | 5 |
molecular techniques | 5 |
cells may | 5 |
directed mutagenesis | 5 |
virus nonstructural | 5 |
rvfv capture | 5 |
chikv nsp | 5 |
schenckii cbs | 5 |
i ifn | 5 |
causal effect | 5 |
weight gain | 5 |
granulosus coproantigens | 5 |
ml streptomycin | 5 |
dna per | 5 |
two years | 5 |
affinity chromatography | 5 |
molecules recognized | 5 |
parental virus | 5 |
studies will | 5 |
burkholderia pseudomallei | 5 |
protein levels | 5 |
environment agency | 5 |
protect viral | 5 |
positive specimens | 5 |
statistically different | 5 |
length rna | 5 |
oocyst excretion | 5 |
chikv co | 5 |
infected cell | 5 |
viral nucleic | 5 |
human serum | 5 |
pcr confirmed | 5 |
bat lyssavirus | 5 |
data demonstrate | 5 |
zikv exposure | 5 |
approved vaccine | 5 |
chinese government | 5 |
conformational changes | 5 |
cell monolayer | 5 |
expected deaths | 5 |
flow cytometer | 5 |
confirmed case | 5 |
autochthonous transmission | 5 |
patients died | 5 |
reaction volume | 5 |
eagle medium | 5 |
two samples | 5 |
feline igg | 5 |
jev mhiaf | 5 |
human patients | 5 |
intact chikv | 5 |
vad diet | 5 |
published studies | 5 |
igg titer | 5 |
virus assembly | 5 |
two hours | 5 |
tsutsugamushi dna | 5 |
live infection | 5 |
virus production | 5 |
arbitrarily set | 5 |
rabies reemergence | 5 |
groups respectively | 5 |
negative results | 5 |
transcription loop | 5 |
also possible | 5 |
diagnostic samples | 5 |
ebolavirus replication | 5 |
amplification using | 5 |
considered statistically | 5 |
length product | 5 |
exact test | 5 |
monitored daily | 5 |
normal donors | 5 |
deficient monocytes | 5 |
modified eagle | 5 |
transcriptional shut | 5 |
home deaths | 5 |
nn peptide | 5 |
blood meal | 5 |
unique vector | 5 |
cruzi dna | 5 |
fusion assay | 5 |
pcr technique | 5 |
sensitive region | 5 |
filarial model | 5 |
arenavirus infection | 5 |
death among | 5 |
two viruses | 5 |
allowed us | 5 |
fitted parameter | 5 |
amplification reaction | 5 |
rickettsial infections | 5 |
treated mice | 5 |
prv strain | 5 |
mosquito species | 5 |
ii viral | 5 |
described earlier | 5 |
cultured cells | 5 |
mm sodium | 5 |
significant changes | 5 |
also indicate | 5 |
denv replication | 5 |
fecal sample | 5 |
data presented | 5 |
systematic analysis | 5 |
rhesus macaques | 5 |
rapid diagnosis | 5 |
eg test | 5 |
cell sorting | 5 |
study period | 5 |
neutralization assay | 5 |
direct rapid | 5 |
immunodominant peptides | 5 |
five times | 5 |
new insights | 5 |
dog population | 5 |
data together | 5 |
may facilitate | 5 |
low level | 5 |
recombinant diii | 5 |
tested positive | 5 |
serial passage | 5 |
rna product | 5 |
prospective studies | 5 |
patient samples | 5 |
also showed | 5 |
control antibodies | 5 |
tissue sections | 5 |
denv mock | 5 |
new virus | 5 |
silac ratio | 5 |
virus virulence | 5 |
similar detection | 5 |
disease transmission | 5 |
tcid units | 5 |
missing values | 5 |
interim guidance | 5 |
plotted using | 5 |
mo group | 5 |
surface antigen | 5 |
organ impairment | 5 |
male bats | 5 |
healthy adults | 5 |
essential role | 5 |
andv stem | 5 |
sex difference | 5 |
small molecules | 5 |
brain homogenates | 5 |
warmer lamp | 5 |
nucleotide sequence | 5 |
chambers implanted | 5 |
water storage | 5 |
vectored vaccines | 5 |
materials analysis | 5 |
chik str | 5 |
control strategies | 5 |
reactive antibodies | 5 |
using different | 5 |
niv antibodies | 5 |
virus detection | 5 |
limit analysis | 5 |
i site | 5 |
carrying nss | 5 |
applied biosystems | 5 |
untreated control | 5 |
rpa assay | 5 |
will continue | 5 |
specific immune | 5 |
provides complete | 5 |
expression vector | 5 |
genome sequence | 5 |
showed significant | 5 |
bloody diarrhea | 5 |
meier survival | 5 |
studies using | 5 |
final volume | 5 |
case series | 5 |
dengue viral | 5 |
ape populations | 5 |
mg mouse | 5 |
urine production | 5 |
asian bats | 5 |
complete genome | 5 |
strain prvabc | 5 |
considered significant | 5 |
expression system | 5 |
lamp method | 5 |
parasite development | 5 |
environmental public | 5 |
state university | 5 |
igg antibodies | 5 |
ms analysis | 5 |
multilocularis metacestodes | 5 |
provide complete | 5 |
prv antigen | 5 |
calculated using | 5 |
fam labeled | 5 |
shock syndrome | 5 |
integrated density | 5 |
pcr based | 5 |
display library | 5 |
done using | 5 |
national newspaper | 5 |
kidney cells | 5 |
virus inactivation | 5 |
spike protein | 5 |
sodium chloride | 5 |
blotting using | 5 |
family members | 5 |
five mice | 5 |
visualized using | 5 |
specific igg | 5 |
granule assembly | 5 |
crude dna | 5 |
related knowledge | 5 |
cibacron blue | 5 |
virus membrane | 5 |
line treatment | 5 |
sanofi pasteur | 5 |
knockout mice | 5 |
based vaccines | 5 |
weeks following | 5 |
infection among | 5 |
interventions required | 5 |
whether zikv | 5 |
disease monitoring | 5 |
lethal morbidity | 5 |
factors associated | 5 |
model calibration | 5 |
master mix | 5 |
needle aspirates | 5 |
pandemic influenza | 5 |
dengue haemorrhagic | 5 |
five days | 5 |
clinical studies | 5 |
containing rvfv | 5 |
infection data | 5 |
new approach | 5 |
proteomic analysis | 5 |
assay using | 5 |
polyclonal antibodies | 5 |
parasite elimination | 5 |
care diagnostic | 5 |
bat hunters | 5 |
uc davis | 5 |
contributed reagents | 5 |
veterinary services | 5 |
european bat | 5 |
primary antibodies | 5 |
intranasal inoculation | 5 |
will provide | 5 |
brown bats | 5 |
dna encoding | 5 |
mayaro virus | 5 |
known contact | 5 |
immune function | 5 |
phylogenetic lineages | 5 |
disulfide bridges | 5 |
game wardens | 5 |
reagents materials | 5 |
molecular methods | 5 |
dub activities | 5 |
strain isolated | 5 |
located within | 5 |
recovered individuals | 5 |
specific binding | 5 |
labeled anti | 5 |
cases may | 5 |
microglial activation | 5 |
mediated cell | 5 |
protein sequence | 5 |
also tested | 5 |
recombinant vaccinia | 5 |
elisa using | 5 |
case report | 5 |
animals belonging | 5 |
protease activity | 5 |
zikv modulates | 5 |
isothermal conditions | 5 |
confocal microscopy | 5 |
particle capture | 5 |
chik vaccinated | 5 |
fgl knock | 5 |
skin rash | 5 |
reservoir hosts | 5 |
incomplete adjuvant | 5 |
worms mouse | 5 |
gorilla fecal | 5 |
flaviviridae family | 5 |
bat exposure | 5 |
epidemic ended | 5 |
best predictors | 5 |
points proposed | 5 |
six animals | 5 |
quantified peptides | 5 |
mg per | 5 |
novel arenavirus | 5 |
lamp reaction | 5 |
stem peptide | 5 |
dna sequence | 5 |
lysed virus | 5 |
survival rates | 5 |
insect cells | 5 |
different cell | 5 |
parameter distributions | 5 |
stress accumulation | 5 |
kit format | 5 |
focus reduction | 5 |
drinking water | 5 |
clinical symptoms | 5 |
likely due | 5 |
pan american | 5 |
sex differences | 5 |
ulcerans disease | 5 |
medical records | 5 |
elevated levels | 5 |
recent decades | 5 |
american health | 5 |
diagnostic tools | 5 |
pathogenic viruses | 5 |
respiratory infection | 5 |
inoculated onto | 5 |
strand displacement | 5 |
limited availability | 5 |
left panel | 5 |
renal syndrome | 5 |
fetal calf | 5 |
andes virus | 5 |
eif alpha | 5 |
vaccination campaign | 5 |
rabies vaccine | 5 |
jefferson university | 5 |
results demonstrated | 5 |
minimum essential | 5 |
nitrocellulose membrane | 5 |
assess whether | 5 |
host antiviral | 5 |
high molecular | 5 |
alanine aminotransferase | 5 |
plasmid clones | 5 |
fatality rates | 5 |
armc patients | 5 |
chikv specific | 5 |
pandemic potential | 5 |
social distancing | 5 |
interval ci | 5 |
domain ii | 5 |
immune mediated | 5 |
zoonotic transmission | 5 |
factor alpha | 5 |
domestic animals | 5 |
significant decrease | 5 |
study sites | 5 |
parvum oocysts | 5 |
chagas non | 5 |
replication competent | 5 |
animal health | 5 |
thomas jefferson | 5 |
immunodiagnostic test | 5 |
using primers | 5 |
protein vaccines | 5 |
dna samples | 5 |
human cell | 5 |
encephalitis caused | 5 |
assessed using | 5 |
factors including | 5 |
cytokine levels | 5 |
using taqman | 5 |
shed gp | 5 |
yap state | 5 |
experimental model | 5 |
data may | 5 |
prv caused | 5 |
east africa | 5 |
serial passages | 5 |
severe clinical | 5 |
parasite antigens | 5 |
less severe | 5 |
microplate reader | 5 |
spleen cell | 5 |
dengue epidemics | 5 |
study demonstrates | 5 |
brugia malayi | 5 |
peptide inhibitors | 5 |
liver disease | 5 |
sirna transfection | 5 |
increased susceptibility | 5 |
restriction site | 5 |
bat cell | 5 |
typhimurium strains | 5 |
search engine | 5 |
asian countries | 5 |
rdrp enzymes | 5 |
classical rabies | 5 |
emerging infections | 5 |
neutralizing monoclonal | 5 |
intraperitoneal inoculation | 5 |
acid residues | 5 |
onnv non | 5 |
collected every | 5 |
results presented | 5 |
dotted line | 5 |
turnaround time | 5 |
analysis showed | 5 |
i interferon | 5 |
clinical disease | 5 |
booster vaccination | 5 |
using two | 4 |
increased viral | 4 |
salmonella typhimurium | 4 |
pcr amplified | 4 |
growth rate | 4 |
vad female | 4 |
virus used | 4 |
outside dhaka | 4 |
one another | 4 |
lethal disease | 4 |
sars coronavirus | 4 |
organ transplantation | 4 |
genes encoding | 4 |
travelers returning | 4 |
viral attachment | 4 |
greater risk | 4 |
seven patients | 4 |
adjusted life | 4 |
chikv strains | 4 |
infectious dose | 4 |
high coverage | 4 |
nasba technique | 4 |
results using | 4 |
host immunity | 4 |
values presented | 4 |
clinical observations | 4 |
varying degrees | 4 |
ubiquitin proteasome | 4 |
public cleanliness | 4 |
nested rt | 4 |
completely block | 4 |
month period | 4 |
quality control | 4 |
new developments | 4 |
fever screening | 4 |
specific region | 4 |
within days | 4 |
epidemiological investigation | 4 |
chikv pseudovirus | 4 |
gc shares | 4 |
cardiac puncture | 4 |
human cd | 4 |
fluorescent signals | 4 |
predicted gc | 4 |
genetically modified | 4 |
alphavirus nsp | 4 |
laboratory practice | 4 |
untranslated regions | 4 |
mpxv challenge | 4 |
mouse cd | 4 |
clinical performance | 4 |
new technologies | 4 |
two additional | 4 |
mapk pathway | 4 |
gp strain | 4 |
search index | 4 |
length protein | 4 |
vaccine efficacy | 4 |
larvae recovered | 4 |
pneumocystis pneumonia | 4 |
washed three | 4 |
brazil zika | 4 |
randomly assigned | 4 |
transcription pcr | 4 |
mda required | 4 |
three major | 4 |
will likely | 4 |
mixture containing | 4 |
time dependent | 4 |
among adults | 4 |
cohort study | 4 |
tissue injury | 4 |
later time | 4 |
poor circulation | 4 |
health operations | 4 |
uc co | 4 |
report form | 4 |
granulocyte dysfunction | 4 |
malaria infection | 4 |
deceased person | 4 |
samples incubated | 4 |
explore factors | 4 |
close contact | 4 |
eliminate dengue | 4 |
explore whether | 4 |
serologic properties | 4 |
national environment | 4 |
statistical difference | 4 |
peak titers | 4 |
infectious agent | 4 |
comparative analysis | 4 |
purified viral | 4 |
tail bats | 4 |
heterogeneous nuclear | 4 |
overall cfr | 4 |
heavy chain | 4 |
mediated immunity | 4 |
transfection cells | 4 |
tested using | 4 |
flow rate | 4 |
virus molecular | 4 |
denv infections | 4 |
virus using | 4 |
parental viruses | 4 |
also able | 4 |
independent experiment | 4 |
molecular identification | 4 |
hek cells | 4 |
carbonate buffer | 4 |
report deaths | 4 |
media data | 4 |
luciferase activity | 4 |
mice humanized | 4 |
significantly affected | 4 |
igm antibodies | 4 |
hochberg procedure | 4 |
fluorescence microscopy | 4 |
charters towers | 4 |
reduced viral | 4 |
experimentally challenged | 4 |
disease progression | 4 |
inactivated virus | 4 |
derived antibodies | 4 |
experimental study | 4 |
associated activity | 4 |
igg antibody | 4 |
immunofluorescence staining | 4 |
viral infectivity | 4 |
surveillance tool | 4 |
sense primer | 4 |
ovarian tumor | 4 |
several different | 4 |
armc network | 4 |
standard nanotrap | 4 |
lyssavirus genotypes | 4 |
single injection | 4 |
cell functions | 4 |
virus exposure | 4 |
factors like | 4 |
mosquito bodies | 4 |
human parvovirus | 4 |
mediated host | 4 |
mediated immune | 4 |
disposable pocket | 4 |
typhus group | 4 |
strains used | 4 |
research council | 4 |
mer full | 4 |
safety concerns | 4 |
congenital zika | 4 |
recombinant virus | 4 |
immunosorbent assays | 4 |
pulmonary lesions | 4 |
made using | 4 |
pfu cell | 4 |
remains controversial | 4 |
study described | 4 |
tract infection | 4 |
calves effect | 4 |
information provided | 4 |
acquired using | 4 |
virus inhibits | 4 |
routine surveillance | 4 |
containing mm | 4 |
national research | 4 |
human case | 4 |
mm dithiothreitol | 4 |
attachment assay | 4 |
jackson immunoresearch | 4 |
bek cells | 4 |
also revealed | 4 |
bekcre cells | 4 |
one study | 4 |
animal species | 4 |
rural areas | 4 |
using trizol | 4 |
antibody levels | 4 |
associated coronavirus | 4 |
north america | 4 |
mouse weights | 4 |
structural genes | 4 |
fecal collection | 4 |
whole genome | 4 |
clinical trial | 4 |
rabies transmission | 4 |
genus alphavirus | 4 |
se asia | 4 |
trypanosoma rangeli | 4 |
tmb substrate | 4 |
protect mice | 4 |
migration pattern | 4 |
virus surveillance | 4 |
depletion studies | 4 |
central african | 4 |
brugia pahangi | 4 |
fatality rate | 4 |
genus flavivirus | 4 |
ml per | 4 |
higher risk | 4 |
high specificity | 4 |
zikv strains | 4 |
locally acquired | 4 |
avian influenza | 4 |
challenge model | 4 |
ml blood | 4 |
mouse experiments | 4 |
shotgun mutagenesis | 4 |
blood mononuclear | 4 |
week time | 4 |
protein domain | 4 |
structural domain | 4 |
metabolic acidosis | 4 |
kda molecule | 4 |
model using | 4 |
disease prevention | 4 |
tissue factor | 4 |
np oligomerisation | 4 |
promoter induction | 4 |
fungal pathogens | 4 |
lethal encephalitis | 4 |
viral structural | 4 |
study conducted | 4 |
greatly reduced | 4 |
ebolavirus exposure | 4 |
performance liquid | 4 |
protective role | 4 |
onnv infection | 4 |
genetic basis | 4 |
well established | 4 |
enveloped virus | 4 |
grand island | 4 |
river virus | 4 |
mathematical models | 4 |
recombinant subunit | 4 |
southern florida | 4 |
ad libitum | 4 |
monitoring data | 4 |
infected fgl | 4 |
th th | 4 |
medical branch | 4 |
detection kit | 4 |
notifiable disease | 4 |
community acceptance | 4 |
antigen detection | 4 |
fecal consistency | 4 |
parasite control | 4 |
purified cchfv | 4 |
treg effector | 4 |
categorical variables | 4 |
chadox gfp | 4 |
blood collection | 4 |
attachment step | 4 |
us dollars | 4 |
enhance viral | 4 |
loop mediated | 4 |
encephalitis viruses | 4 |
efficient replication | 4 |
prevalence threshold | 4 |
genus phlebovirus | 4 |
among cases | 4 |
specific cellular | 4 |
providing additional | 4 |
following day | 4 |
fatal encephalitis | 4 |
mediated fusion | 4 |
franklin lakes | 4 |
one month | 4 |
generated two | 4 |
escherichia coli | 4 |
leading cause | 4 |
event dog | 4 |
lf transmission | 4 |
early time | 4 |
rad laboratories | 4 |
minimally invasive | 4 |
chronic helminth | 4 |
observational studies | 4 |
baidu search | 4 |
traditional burial | 4 |
rdrp complex | 4 |
one step | 4 |
passage virus | 4 |
response capacity | 4 |
sirna knockdown | 4 |
biosafety measures | 4 |
new zealand | 4 |
fever outbreaks | 4 |
positive pcr | 4 |
intracellular staining | 4 |
humanized nsg | 4 |
imagej analysis | 4 |
four serotypes | 4 |
tag peptide | 4 |
infections occur | 4 |
densitometry quantification | 4 |
mandibular salivary | 4 |
old cd | 4 |
dengue afi | 4 |
control diets | 4 |
dna detection | 4 |
may cause | 4 |
control sirna | 4 |
untreated cells | 4 |
clinical relevance | 4 |
lactate dehydrogenase | 4 |
supplemented dmem | 4 |
lost weight | 4 |
also included | 4 |
niv antibody | 4 |
becoming cases | 4 |
endotracheal intubation | 4 |
animal bites | 4 |
inhibitor cc | 4 |
rpa methods | 4 |
conducted using | 4 |
positive predictors | 4 |
prothrombin time | 4 |
also thank | 4 |
log pfu | 4 |
recombinant marburg | 4 |
single cell | 4 |
statistical significance | 4 |
bst dna | 4 |
predictions made | 4 |
trypanosoma brucei | 4 |
derived mutant | 4 |
weeks old | 4 |
epifil model | 4 |
iu ml | 4 |
sucrose gradient | 4 |
system dynamics | 4 |
clinical microbiology | 4 |
two closely | 4 |
viral gene | 4 |
human mpx | 4 |
seasonal influenza | 4 |
activity groups | 4 |
linking mass | 4 |
human population | 4 |
rna load | 4 |
ebolavirus species | 4 |
experimental mouse | 4 |
negative test | 4 |
oocysts enumerated | 4 |
flag mouse | 4 |
elisa kit | 4 |
perivascular infiltrates | 4 |
protein concentrations | 4 |
five freedoms | 4 |
largest epidemic | 4 |
kdna pcr | 4 |
bats may | 4 |
high cost | 4 |
enhanced denv | 4 |
skin lesions | 4 |
virus full | 4 |
detection method | 4 |
cfr among | 4 |
risk period | 4 |
dengue surveillance | 4 |
cell type | 4 |
young mouse | 4 |
federated states | 4 |
immunohistochemical staining | 4 |
recombinant fgl | 4 |
helminth infections | 4 |